the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Melanoma (skin) Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
CIRB15-1777 Luke, Jason S1404: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma Details
Phase II
Study No PI Title
IRB15-1788 Luke, Jason Phase II Study of Pembrolizumab and Ipilimumab following Initial Anti-PD1/L1 Antibody Details
CIRB15-1357 Luke, Jason EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
IRB15-0650 Luke, Jason A Phase Ib/II Clinical Study of BBI608 Administered in Combination with Immune Checkpoint Inhibitors to Adult Patients with Advanced Cancers Details
IRB15-0835 Luke, Jason A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma Details
IRB15-0718 Luke, Jason A Phase II Study of Glembatumumab Vedotin, an AntigpNMB Antibody-Drug Conjugate, in Patients with Advanced Melanoma (CDX011-05) Details
IRB15-0658 Luke, Jason A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients with Advanced Uveal Melanoma Details
IRB14-0704 Gajewski, Thomas A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors Details
Phase I
Study No PI Title
IRB16-0538 Luke, Jason A Multi-Center, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies Whose Disease has Progressed on PD-1 or PD-L1 Immune Checkpoint Inhibitors Details
IRB16-0263 Luke, Jason A Phase I, Open-Label, Dose Escalation Study of MGA271 in Combination with Ipilimumab in Patients with B7-H3-expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-small Cell Lung Cancer, and Other B7-H3-Expressing Cancers Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
IRB15-1807 Luke, Jason A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas Details
IRB15-1767 Luke, Jason A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers Details
IRB15-1022 Luke, Jason A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab with or without Bevacizumab in Patients with Locally Advanced or Metastatic Solid Tumors Details
IRB15-1024 Luke, Jason A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors Details
IRB15-1130 Luke, Jason Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors Details
IRB15-0650 Luke, Jason A Phase Ib/II Clinical Study of BBI608 Administered in Combination with Immune Checkpoint Inhibitors to Adult Patients with Advanced Cancers Details
IRB15-0835 Luke, Jason A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma Details
IRB15-0091 Nanda, Rita An Open-label, Dose-escalation/expansion, Phase 1 Study of ASP4132, Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma Details
IRB14-0894 Gajewski, Thomas A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors Details
IRB14-0704 Gajewski, Thomas A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors Details
IRB14-0105 Szmulewitz, Russell A Phase 1, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3 Details
IRB14-0105 Szmulewitz, Russell A Phase I, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms whose Vasculature Expresses B7-H3 Details
IRB13-0936 Gajewski, Thomas A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors Details


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .